文献速递肺结节与肺癌

体细胞突变与免疫检查点生物标志物的分子检测技术综述

Somatic mutations and immune checkpoint biomarkers.
PubMed 文献 · Respirology · 2019-01-12

本文综述非小细胞肺癌中体细胞突变与免疫检查点生物标志物的分子检测技术,涵盖免疫组化、荧光原位杂交、直接测序、实时PCR、变性高效液相色谱、质谱及二代测序等方法,讨论各技术在临床选择中受成本、技术专长、仪器配置和样本类型影响,并强调PD-L1免疫组化标准化对免疫检查点抑制剂治疗决策的重要性。

要点

  • 免疫组化常规用于EGFR、ALK和PD-L1靶向改变的分类与鉴别。
  • 直接测序曾是EGFR、KRAS、BRAF突变检测金标准但已被更敏感方法取代。
  • 二代测序可高通量覆盖常突变基因包括BRAF、MET及抑癌基因改变。

核心结论

  • 分子检测技术指导非小细胞肺癌个体化治疗,技术选择受成本、专长、仪器和样本类型影响。
  • PD-L1通路被肿瘤细胞利用实现免疫抵抗,免疫检查点抑制剂治疗需标准化免疫组化检测。
  • 二代测序可高通量检测包括BRAF、MET及抑癌基因在内的多种突变。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 免疫组化常规用于EGFR、ALK和PD-L1靶向改变的分类、鉴别、组织学及鉴定。
  • 直接测序历史上是EGFR、KRAS和BRAF突变检测金标准,需高肿瘤与正常细胞比例。
  • 二代测序为新兴技术,可高通量覆盖常突变基因包括较少见的BRAF和MET突变及抑癌基因改变。
  • 无二代测序平台时,基于PCR的技术提供高效经济的单基因检测指导患者治疗。

临床怎么用

  • 临床应根据成本、技术专长、仪器配置和样本类型选择分子检测方法。
  • 免疫组化用于EGFR、ALK和PD-L1靶向改变的常规分类与鉴定。
  • 无二代测序平台时可选用基于PCR的技术进行单基因检测指导治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of molecular testing for identifying somatic mutations and immune checkpoint biomarkers has directed treatment towards personalized medicine for patients with non-small cell lung cancer. The choice of molecular testing in a clinical setting is influenced by cost, expertise in the technology, instrumentation setup and sample type availability. The molecular techniques described in this review include immunohistochemistry (IHC), fluorescent in situ hybridization, direct sequencing, real-time polymerase chain reaction (PCR), denaturing high-performance liquid chromatography, matrix-assisted laser desorption/ionization time of flight mass spectrometry and next-generation sequencing (NGS). IHC is routinely used in clinical practice for the classification, differentiation, histology and identification of targetable alterations of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and programmed death ligand-1 (PD-L1). Recently, the PD-L1 pathway was identified as being exploited by tumour cells, allowing immune resistance and tumour evasion. The development of immune checkpoint inhibitors as treatment for tumours expressing checkpoints has highlighted the need for standardized IHC assays to inform treatment decisions for patients. Direct sequencing was historically the gold standard for mutation testing for EGFR, KRAS (Kirsten rat sarcoma viral oncogene homologue) and BRAF (v-Raf murine sarcoma viral oncogene homologue B1) requiring a high ratio of tumour to normal cells, but this has been superseded by more sensitive methods. NGS is a new emerging technique, which allows high-throughput coverage of frequently mutated genes, including less common BRAF and MET mutations and alterations in tumour suppressor genes. When an NGS platform is unavailable, PCR-based technologies offer an efficient and cost-effective single gene test to guide patient treatment. This article will review these techniques and discuss the future of molecular platforms underpinning clinical management decisions.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Parris BA, Shaw E, Pang B, et al. Somatic mutations and immune checkpoint biomarkers. Respirology. 2019. PMID: 30636374. doi:10.1111/resp.13463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。